SG
TOVX icon

StoneX Group’s Theriva Biologics TOVX Stock Holding History

StoneX Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.36K Sell
22,280
-14,937
-40% -$2.94K ﹤0.01% 886
2025
Q4 		$7.83K Buy
+37,217
New +$11K ﹤0.01% 1014

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

StoneX Group's TOVX Position: Q1 2026 in Review

StoneX Group reduced its Theriva Biologics (TOVX) stake by 40% in Q1 2026, selling an estimated $2.94K and leaving 22,280 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

StoneX Group first reported a position in TOVX in Q4 2025 and has held it in 2 quarters since. The position peaked at $7.83K in Q4 2025. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • StoneX Group held 22,280 shares of Theriva Biologics worth $4.36K as of Q1 2026.
  • StoneX Group sold 14,937 Theriva Biologics shares in Q1 2026, an estimated $2.94K.
  • Theriva Biologics made up ﹤0.01% of StoneX Group's portfolio in Q1 2026, its #886 holding.
  • StoneX Group first reported a position in Theriva Biologics in Q4 2025 and has held it in 2 quarters since.
  • StoneX Group's Theriva Biologics position peaked at $7.83K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.